Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDLTSE:CXFNASDAQ:IPATSE:ITH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.46+1.4%$1.13$0.77▼$3.00$120.67M1.03340,088 shs176,468 shsCXFCI Canadian Convertible Bond ETF CommonC$10.21+0.1%C$9.99C$9.56▼C$10.57C$51.61MN/A4,438 shs500 shsIPAImmunoPrecise Antibodies$0.70-3.9%$0.50$0.27▼$1.08$32.10M0.122.43 million shs3.61 million shsITHInternational Tower Hill MinesC$1.27+0.8%C$1.04C$0.57▼C$1.48C$178.30M1.1735,129 shs1,600 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+2.86%+4.35%+25.76%+27.43%-51.52%CXFCI Canadian Convertible Bond ETF Common-0.10%+0.29%+2.10%+2.72%+4.94%IPAImmunoPrecise Antibodies+21.57%+4.27%+46.86%+89.63%-29.82%ITHInternational Tower Hill Mines-0.79%-3.08%+21.15%+34.04%+72.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics2.2198 of 5 stars3.72.00.00.03.10.00.6CXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies2.7198 of 5 stars3.53.00.00.03.10.01.3ITHInternational Tower Hill MinesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.40Buy$8.67493.61% UpsideCXFCI Canadian Convertible Bond ETF Common 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.00470.21% UpsideITHInternational Tower Hill Mines 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CXF, ITH, IPA, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/1/2025IPAImmunoPrecise AntibodiesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.003/31/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.003/14/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ACXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies$24.00M1.34N/AN/A$0.93 per share0.75ITHInternational Tower Hill MinesN/AN/AC$0.06 per share22.50C$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)CXFCI Canadian Convertible Bond ETF CommonN/AN/A0.00∞N/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-114.50%-73.74%-42.68%7/3/2025 (Estimated)ITHInternational Tower Hill Mines-C$2.36M-C$0.02N/A∞N/AN/A-5.82%-3.65%N/ALatest CXF, ITH, IPA, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/A3/28/2025Q3 2025IPAImmunoPrecise Antibodies-$0.06-$0.06N/A-$0.46$6.59 million$4.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACXFCI Canadian Convertible Bond ETF CommonC$0.484.70%N/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.012.492.49CXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AIPAImmunoPrecise Antibodies0.361.010.85ITHInternational Tower Hill MinesN/A10.3730.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%CXFCI Canadian Convertible Bond ETF CommonN/AIPAImmunoPrecise Antibodies6.70%ITHInternational Tower Hill Mines71.80%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%CXFCI Canadian Convertible Bond ETF CommonN/AIPAImmunoPrecise Antibodies6.83%ITHInternational Tower Hill Mines0.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.65 million78.27 millionNot OptionableCXFCI Canadian Convertible Bond ETF Common905.05 millionN/ANot OptionableIPAImmunoPrecise Antibodies8045.77 million28.94 millionNot OptionableITHInternational Tower Hill Mines220140.40 millionN/ANot OptionableCXF, ITH, IPA, and CRDL HeadlinesRecent News About These CompaniesInternational Tower Hill Mines (TSE:ITH) Stock Crosses Above Two Hundred Day Moving Average - Here's What HappenedJune 11 at 6:28 AM | marketbeat.comInternational Tower Hill Mines (TSE:ITH) Reaches New 12-Month High - Still a Buy?June 4, 2025 | marketbeat.comInternational Tower Hill Mines (TSE:ITH) Shares Cross Above 50-Day Moving Average - Should You Sell?May 19, 2025 | marketbeat.comInternational Tower Hill Mines Files 2025 First Quarter Financial ResultsMay 9, 2025 | finance.yahoo.comInternational Tower Hill Mines Ltd. (THM): Among Billionaire John Paulson’s Stocks with Huge Upside PotentialMay 7, 2025 | uk.finance.yahoo.comTrump signs order seeking to jump-start mining of the ocean floorApril 25, 2025 | msn.comInternational mining giant dropping out of partnership in Alaska gold mining projectApril 24, 2025 | alaskabeacon.comWhy International Tower Hill Mines Ltd.’s (THM) Stock Is Up 8.29%April 12, 2025 | aaii.comInternational Tower Hill Mines Approves 2025 Livengood Gold Project Work Plan and Files 2024 Year End Financial ResultsMarch 12, 2025 | ca.finance.yahoo.comInternational Tower Hill Mines announces $3.9M non-brokered private placementMarch 4, 2025 | markets.businessinsider.com7 Most Obscure Towns In America You Wouldn't Think To VisitNovember 7, 2024 | msn.comHedge funds investors control 32% of International Tower Hill Mines Ltd. (TSE:ITH) and were rewarded last week after stock increased 44%October 17, 2024 | finance.yahoo.comJust Over the Border from Israel, a Hezbollah Cache of Explosives and MinesOctober 14, 2024 | nytimes.comPrince Harry Is Keeping Princess Diana's Landmine Legacy Alive: 'He Wants to Finish the Job' (Exclusive)September 29, 2024 | people.comDozens of Massachusetts lawmakers tell RMV to hit the brakes on revoking CDLsSeptember 27, 2024 | ca.news.yahoo.comAfter personal appeal from Zelensky, Trump agrees to meet with the Ukrainian president after allSeptember 27, 2024 | washingtonexaminer.com8 Theme Parks That Go All Out for Halloween and ChristmasSeptember 25, 2024 | msn.comElection 2024 live updates: Trump returns to N.C.; Harris delivering economic address in Pa.September 25, 2024 | msn.comIran believes all remaining workers have died in coal mine explosion, raising death toll to 49September 24, 2024 | thehill.comIran methane leak causes coal mine explosion, killing at least 30September 22, 2024 | msn.comAt least 19 killed as methane leak causes explosion at eastern Iran coal mine, state TV reportsSeptember 22, 2024 | abcnews.go.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst OptimismQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationTop 5 Stocks Hedge Funds Are Buying Right NowBy Ryan Hasson | May 20, 2025View Top 5 Stocks Hedge Funds Are Buying Right NowBroadcom Set to Surge as AI Diffusion Rule EndsBy Leo Miller | May 15, 2025View Broadcom Set to Surge as AI Diffusion Rule EndsCXF, ITH, IPA, and CRDL Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.46 +0.02 (+1.39%) Closing price 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.30%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.CI Canadian Convertible Bond ETF Common TSE:CXFC$10.21 +0.01 (+0.10%) As of 03:56 PM EasternChimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.ImmunoPrecise Antibodies NASDAQ:IPA$0.70 -0.03 (-3.89%) Closing price 04:00 PM EasternExtended Trading$0.69 -0.01 (-1.50%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.International Tower Hill Mines TSE:ITHC$1.27 +0.01 (+0.79%) As of 03:39 PM EasternInternational Tower Hill Mines Ltd. engages in the acquisition, exploration, and development of mineral properties. It holds rights to acquire interests in the Livengood gold project covering an area of approximately 19,546 hectares located to the northwest of Fairbanks, Alaska. The company was formerly known as Tower Hill Mines Ltd. and changed its name to International Tower Hill Mines Ltd. in March 1991. International Tower Hill Mines Ltd. was incorporated in 1978 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
